Role of Tumoral Biomarker B3 Adrenergic Receptor in Paediatric Solid Tumours

Launched by MEYER CHILDREN'S HOSPITAL IRCCS · Mar 8, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at a specific protein called the β3 adrenergic receptor (β3AR) and its role in solid tumors in children. Researchers want to understand how this protein might influence the growth and behavior of these tumors. They will collect samples, like blood and tumor tissue, from children and young adults with certain types of cancers, such as Wilms' tumor, Ewing's Sarcoma, and Neuroblastoma, to see how the levels of this protein compare to healthy individuals. The aim is to find new ways to predict how aggressive a tumor might be and to identify potential new treatments.

To participate in this study, patients need to be between 0 and 20 years old and have been diagnosed with one of the specified cancers since 2015. Parents or guardians will need to provide consent for younger patients, while those over 18 can consent for themselves. Participants will be monitored for five years, and they will need to provide enough blood and tumor samples for the research. It’s important to note that certain health conditions, like specific viral infections or pregnancy, may prevent someone from joining the study. This research could help improve our understanding of childhood cancers and lead to better outcomes for young patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria (principal study):
• • Diagnoses, received after the year 2015 (Wilms' tumour, Ewing's Sarcoma, Osteosarcoma, Soft tissue sarcomas, Carcinomas, Neuroblastoma)
• • Informed consent signed by parents or the patient if over 18 years of age
• • Planned follow-up for 5 years
• • Availability of a sufficient peripheral blood sample for analysis at onset.
• • Age between 0 and 20 years
• Inclusion Criteria (substudy):
• • Diagnosis of Ewing's Sarcoma, Neuroblastoma, Paediatric leukaemia, Tumours of the breast, lung, colon and ovary
• • Informed consent signed by parents or by the patient if 18 years of age19
• • Planned follow-up for 5 years
• • Availability of biological samples (peripheral blood, bone marrow blood, biopsy at onset) sufficient for the study investigations.
• • Age between 0 and 20 years for paediatric patients referred to CROP Centres - Florence and Pisa
• • Age between 19 and 75 years for adult patients attending the San Donato Hospital in Arezzo
• • Inclusion criteria (control group)
• • Age between 0 and 30 years
• • No evidence of acute or chronic infectious/inflammatory disease
• Exclusion Criteria (for every partecipants to the principal study and substudy):
• • Patients with HIV, HCV and HBV seropositivity (HBSAg) due to biohazard and bias related to patients' immunological status that could influence gene expression and tumour behaviour.
• • Pregnant or lactating patients as the altered hormonal panel is a factor disturbing the expression of β3ARs